THE SELECTION AND USE OF ESSENTIAL MEDICINES

Report of the WHO Expert Committee, 2002
(including the 12th Model List of Essential Medicines)
## Contents

1. Introduction

2. Open session

3. The new procedures for updating and disseminating the Model List
   3.1 Background
   3.2 Key features of the new procedures
   3.3 Review of the new procedures
      3.3.1 Applications for additions
      3.3.2 Applications for deletions
      3.3.3 Selection criteria
   3.4 The WHO model formulary
   3.5 The WHO Essential Medicines Library

4. Other outstanding technical issues
   4.1 Change of name of the Expert Committee
   4.2 Description of essential medicines
   4.3 Role of treatment costs in relation to the Model List
   4.4 Inclusion of additional items in the Model List

5. Format and presentation of the 12th Model List
   5.1 Section headings
   5.2 The core and complementary lists
   5.3 The “square box” symbol

6. Changes made in revising the Model List
   6.1 Applications for additions
      6.1.1 Antiretroviral medicines
      6.1.2 Artemether + lumefantrine (fixed-dose combination)
      6.1.3 α/β-Arteether
      6.1.4 Artemotil (β-arteether)
      6.1.5 Amodiaquine
      6.1.6 Insecticide-treated bednets
      6.1.7 Miconazole nitrate buccal tablets
   6.2 Applications for deletions
   6.3 Other changes
      6.3.1 Meglumine antimoniate
      6.3.2 Antineoplastic and immunosuppressive medicines
      6.3.3 Reserve list medicines

7. Future reviews of sections of the Model List
   7.1 Update on the review of medicines for the treatment of hypertension
   7.2 Review of the core and complementary lists
   7.3 Review of the use of the “square box” symbol
   7.4 Review of injectable medicines
   7.5 Priorities for further systematic reviews
8. **Recommendations**

8.1 Procedures for updating and disseminating the Model List of Essential Medicines 31

8.2 Description of essential medicines 32

8.3 Presentation of the 12th Model List 32

8.4 Additions and changes to the Model List 32

8.5 Deferred applications 33

8.6 Rejected applications 34

8.7 Priorities for future reviews of sections of the Model List 34

8.8 Change of name of the Expert Committee 34

8.9 Other recommendations 34

**Acknowledgements** 35

**References** 35

**Annex 1**
The 12th WHO Model List of Essential Medicines 37

**Annex 2**
Additional notes on the medicines recommended for inclusion in the 12th WHO Model List of Essential Medicines 88

**Annex 3**
The Anatomical Therapeutic Chemical (ATC) classification system 99

Alphabetical list of essential medicines (with ATC classification codes) 119
WHO Expert Committee on the Selection and Use of Essential Medicines
Geneva, 15–19 April 2002

Members*

Professor P.M. de Buschiazzo, Department of Pharmacology, School of Medicine, University of La Plata, La Plata, Argentina (Co-chairperson)

Professor T. Fukui, Department of General Medicine and Clinical Epidemiology, Kyoto University Graduate School of Medicine, Kyoto, Japan

Professor A. Helali, Director, Centre National de Pharmacovigilance et Matérovigilance, Ministère de la Santé et de la Population, Algiers, Algeria

Professor R. Laing, Boston University School of Public Health, Boston, MA, USA (Co-rapporteur)

Professor J.-R. Laporte, Director, Fundacio Institut Català de Farmacologia, Department of Pharmacology and Therapeutics, Universitat Autonoma de Barcelona, Barcelona, Spain (Co-chairperson)

Professor D. Ofori-Adjei, Director, Noguchi Memorial Institute for Medical Research, University of Ghana, Accra, Ghana

Dr E.M.A. Ombaka, Coordinator, Eucumenical Pharmaceutical Network, World Council of Churches, Nairobi, Kenya

Professor M.M. Reidenberg, Chief, Division of Clinical Pharmacology, The New York Hospital – Cornell Medical Centre, New York, NY, USA

Professor S. Suryawati, Director, Centre for Clinical Pharmacology and Drug Policy Studies, Gadjah Mada University, Yogyakarta, Indonesia (Co-rapporteur)

Dr L. Wannmacher, Department of Clinical Pharmacology, School of Medicine, University of Passo Fundo, Rio Grande do Sul, Brazil

Representatives of other organizations†‡

Joint United Nations Programme on HIV/AIDS (UNAIDS)
Dr C. Michon, Care Adviser, UNAIDS, Geneva, Switzerland

United Nations Children’s Fund (UNICEF)
Ms Thuy Huong Ha, Supply Division, UNICEF, Copenhagen, Denmark

WHO Collaborating Centre for Drug Statistics Methodology
Ms M. Rønning, WHO Collaborating Centre for Drug Statistics Methodology, Oslo, Norway

* Each Member of the Committee signed a statement that he or she agreed not to participate in the review of any matter under consideration in which there was a real or perceived conflict of interest. Two Members reported an interest but no real or perceived conflicts of interest were disclosed.


‡ Each representative of other organizations signed a statement that he or she agreed not to participate in the review of any matter under consideration in which there was a real or perceived conflict of interest. One representative reported an interest but no real or perceived conflicts of interest were disclosed.
WHO Collaborating Centre for International Drug Monitoring (Uppsala, Sweden)
Professor C.J. van Boxtel, Professor of Clinical Pharmacology, Amsterdam, Netherlands

Secretariat*

Dr R.C.F. Gray, Medical Officer, Policy, Access and Rational Use, Department of Essential Drugs and Medicines Policy, WHO, Geneva, Switzerland

Professor D. Henry, Medical Officer, Policy, Access and Rational Use, Department of Essential Drugs and Medicines Policy, WHO, Geneva, Switzerland (Temporary Adviser)

Dr S. Hill, Faculty of Health, University of Newcastle, Waratah, NSW, Australia (Temporary Adviser)

Dr H.V. Hogerzeil, Coordinator, Policy, Access and Rational Use, Department of Essential Drugs and Medicines Policy, WHO, Geneva, Switzerland (Secretary)

Professor J.M. Makinde, Head, Department of Pharmacology and Therapeutics, University of Ibadan, Ibadan, Nigeria (Temporary Adviser)

Mr D.K. Mehta, Executive Editor, British national formulary, Royal Pharmaceutical Society, London, England (Temporary Adviser)

Dr P. Mugyenyi, Joint Clinical Research Centre, Kampala, Uganda (Temporary Adviser)

Dr S.L. Nightingale, Department of Health and Human Services, Washington, DC, USA (Temporary Adviser)

Dr S. Sharma, Delhi Society for the Promotion of Rational Use of Drugs, New Delhi, India (Temporary Adviser)

Dr K. Weerasuriya, Regional Adviser, Essential Drugs and Medicines Policy, WHO Regional Office for South-East Asia, New Delhi, India

Mr P.J. Wiffen, Coordinating Editor, Pain, Palliative and Supportive Care, Cochrane Collaborative Review Group, Pain Research Unit, Churchill Hospital, Oxford, England (Temporary Adviser)

* Each Temporary Adviser of the Committee signed a statement that he or she agreed not to participate in the review of any matter under consideration in which there was a real or perceived conflict of interest. No real or perceived conflicts of interest were disclosed.